The Joint Corp. Reports First Quarter 2017 Financial Results
Revenue Increased 33% to $5.7 Million Compared to Prior Year Period
Added 12 new Franchise Clinics in First Quarter
System-wide Comp Sales1 of 19%
SCOTTSDALE, Ariz., May 11, 2017 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ:JYNT), a national operator, manager and franchisor of chiropractic clinics, today reported results for the first quarter ended March 31, 2017.
First Quarter 2017 Financial Highlights
- Revenue increased 33% in the first quarter to $5.7 million, up from $4.3 million in the prior year first quarter
- System-wide comp sales were 19%
- Net loss improved 53% compared to the same quarter last year to ($1.6) million
- Added 12 new franchised clinics, ending the first quarter of 2017 with 373 total clinics in operation, a net increase of 42 total clinics from March 31, 2016
“We continued our progress toward profitability in the first quarter,” said Peter D. Holt, president and chief executive officer of The Joint Corp. “First quarter results reflect continued strong growth in our business as system-wide comp sales were 19% and revenue growth was 33%, in both cases as compared with the first quarter of last year. For the remainder of the year we are focused on achieving profitability in our corporate clinic segment, expanding our franchise network by adding 50 to 60 new franchised clinics in 2017, and continuing to control operating costs.”
Holt added, “Based upon our current core customer profile and usage, we have identified the opportunity to expand to more than 1,700 clinics across the country. With 373 clinics today, the road before us is clear. To fully capitalize on this opportunity, we will focus on rapid expansion through our franchising efforts, amplified by our network of strategically located company-owned or managed clinics.”
 Comp sales refers to the amount of sales a clinic generates in the most recent accounting period, compared to sales in the comparable period of the prior year, and (i) includes sales only from clinics that have been open at least 13 full months and (ii) excludes any clinics that have closed.
First Quarter 2017 Financial Results
Revenue for the first quarter of 2017 increased 33% to $5.7 million from $4.3 million in the first quarter of 2016 due primarily to increasing sales in our existing company-owned or managed clinics and the net increase of 42 clinics since March 31, 2016.
Cost of revenue in the first quarter of 2017 was virtually unchanged compared to the first quarter of 2016 as lower regional developer commissions from fewer clinic openings were offset by higher regional developer royalties.
Selling and marketing expenses increased by 30% to $1.0 million in the first quarter of 2017, compared to $0.7 million in the same period last year primarily due to increases in our national marketing program.
General and administrative expenses decreased to $4.6 million in the first quarter of 2017, compared to $5.7 million in the first quarter of 2016 due to lower payroll and lower legal and accounting expenses. Loss on disposition or impairment was $0.4 million in the first quarter 2017 due to exit cost obligations from the closure of company managed clinics in Chicago and New York.
Depreciation and amortization expenses for the first quarter of 2017 were stable compared to the prior year quarter.
Net loss in the first quarter of 2017 was ($1.6) million, or ($0.13) per share, compared to a net loss of ($3.5) million, or ($0.28) per share, in the same period last year.
Adjusted EBITDA (a non-GAAP measure) in the first quarter of 2017 was ($0.5) million, a significant improvement compared to ($2.7) million in the same quarter last year.
As of March 31, 2017, cash and cash equivalents were $2.7 million, compared to $3.0 million at December 31, 2016. Pursuant to the terms of our credit agreement, we borrowed a required $1.0 million on our line of credit, which remains unused as part of cash and cash equivalents on our balance sheet as of March 31, 2017.
2017 Financial Guidance
For full year 2017, we are reiterating our guidance set forth below:
- Total revenues in the range of $22 million to $24 million
- Adjusted EBITDA in the range of ($1.5) million to ($0.5) million
- Net new franchise clinic openings in the range of 50 to 60
The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, May 11, 2017, to discuss the first quarter 2017 results. The conference call may be accessed by dialing 765-507-2604 or 844-464-3931, and referencing 97364518. A live webcast of the conference call will also be available on the investor relations section of the Company’s website at www.thejoint.com. An audio replay will be available two hours after the conclusion of the call through May 18, 2017. The replay can be accessed by dialing 404-537-3406 or 855-859-2056. The passcode for the replay is 97364518.
Non-GAAP Financial Information
This earnings release includes a presentation of EBITDA and Adjusted EBITDA which are non-GAAP financial measures. These are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company’s underlying operating performance and operating trends. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented within the tables below. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, loss on disposition or impairment, and stock-based compensation expenses. The Company defines EBITDA as net income (loss) before net interest, taxes, depreciation, and amortization expenses.
EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company’s financial statements filed with the SEC.
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our failure to develop or acquire corporate clinics as rapidly as we intend, our failure to profitably operate corporate clinics, and the factors described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.
About The Joint Corp. (NASDAQ:JYNT)
Based in Scottsdale, Arizona, The Joint is reinventing chiropractic by making quality care convenient and affordable for patients seeking pain relief and ongoing wellness. A no-appointment policy and convenient hours and locations make care more accessible, and affordable membership plans and packages eliminate the need for insurance. With 370+ clinics nationwide and more than 4 million patient visits annually, The Joint is an emerging growth company and key leader in the chiropractic profession. For more information, visit www.thejoint.com or follow the brand on Twitter, Facebook, YouTube and LinkedIn.
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In California, Colorado, Florida, Illinois, Minnesota, New Jersey, New York, North Carolina, Oregon and Tennessee, The Joint and its franchisees provide management services to affiliated professional chiropractic practices.
|THE JOINT CORP. AND SUBSIDIARY|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|March 31,||December 31,|
|Cash and cash equivalents||$||2,676,607||$||3,009,864|
|Accounts receivable, net||1,189,132||1,021,733|
|Income taxes receivable||3,054||42,014|
|Notes receivable - current portion||30,818||40,826|
|Deferred franchise costs - current portion||686,873||748,300|
|Prepaid expenses and other current assets||893,520||499,525|
|Total current assets||5,792,555||5,696,656|
|Property and equipment, net||4,360,900||4,724,706|
|Deferred franchise costs, net of current portion||738,258||836,350|
|Intangible assets, net||2,164,066||2,338,922|
|Deposits and other assets||667,021||707,889|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Co-op funds liability||95,007||73,246|
|Notes payable - current portion||168,000||331,500|
|Deferred rent - current portion||148,564||215,450|
|Deferred revenue - current portion||2,866,880||3,077,430|
|Other current liabilities||54,479||60,894|
|Total current liabilities||4,980,743||5,863,884|
|Revolving credit - notes payable||1,000,000||-|
|Deferred rent, net of current portion||907,723||1,400,790|
|Deferred revenue, net of current portion||2,695,729||2,231,712|
|Deferred tax liability||156,920||120,700|
|Commitments and contingencies|
|Series A preferred stock, $0.001 par value; 50,000|
|shares authorized, 0 issued and outstanding, as of March 31, 2017,|
|and December 31, 2016||-||-|
|Common stock, $0.001 par value; 20,000,000 shares|
|authorized, 13,371,535 shares issued and 13,075,031 shares outstanding|
|as of March 31, 2017 and 13,317,393 shares issued and 13,020,889|
|outstanding as of December 31, 2016||13,371||13,317|
|Additional paid-in capital||36,609,876||36,398,588|
|Treasury stock 296,504 shares as of March 31, 2017 and December 31, 2016||(503,118||)||(503,118||)|
|Total stockholders' equity||5,489,691||6,925,413|
|Total liabilities and stockholders' equity||$||16,473,138||$||17,054,861|
|THE JOINT CORP. AND SUBSIDIARY|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|Three Months Ended|
|Revenues and management fees from company clinics||$||2,515,601||$||1,658,553|
|Advertising fund revenue||598,436||265,721|
|IT related income and software fees||267,013||221,134|
|Regional developer fees||76,896||147,537|
|Cost of revenues:|
|Franchise cost of revenues||683,243||694,735|
|IT cost of revenues||58,861||45,228|
|Total cost of revenues||742,104||739,963|
|Selling and marketing expenses||958,706||738,683|
|Depreciation and amortization||577,987||575,544|
|General and administrative expenses||4,564,079||5,692,056|
|Total selling, general and administrative expenses||6,100,772||7,006,283|
|Loss on disposition or impairment||417,971||-|
|Loss from operations||(1,586,990||)||(3,481,210||)|
|Other (expense) income, net||(19,465||)||473|
|Loss before income tax expense||(1,606,455||)||(3,480,737||)|
|Income tax expense||(40,609||)||(44,397||)|
|Net loss and comprehensive loss||$||(1,647,064||)||$||(3,525,134||)|
|Loss per share:|
|Basic and diluted loss per share||$||(0.13||)||$||(0.28||)|
|Basic and diluted weighted average shares||13,042,595||12,567,901|
|Non-GAAP Financial Data:|
|Net income (loss)||$||(1,647,064||)||$||(3,525,134||)|
|Depreciation and amortization expense||577,987||575,544|
|Tax expense (benefit) penalties and interest||40,609||44,397|
|Stock compensation expense||95,065||197,668|
|Acquisition related expenses||12,650||30,861|
|Loss on disposition or impairment||417,971||-|
The above table presents the reconciliation of net income (loss) to Adjusted EBITDA for the three month periods ended March 31, 2017 and 2016.
|THE JOINT CORP. AND SUBSIDIARY|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Three Months Ended|
|Adjustments to reconcile net loss to net cash||1,127,243||732,113|
|Changes in operating assets and liabilities||(736,896||)||(2,966,707||)|
|Net cash used in operating activities||(1,256,717||)||(5,759,728||)|
|Net cash used in investing activities||(29,317||)||(545,684||)|
|Net cash provided by (used in) financing activities||952,777||(119,942||)|
|Net decrease in cash||$||(333,257||)||$||(6,425,354||)|
Investor Contact: Peter Vozzo [email protected] 443-213-0505 Media Contact: Inna Lazarev Public Relations Manager [email protected]
Released May 11, 2017